Ovarian Cancer Coverage from Every Angle
Advertisement
Advertisement

Published Medical Literature

Can HIPEC Plus Cytoreductive Therapy Improve Outcomes in Recurrent Ovarian Cancer?
Predicting Prognosis in HGSOC: Focus on Myeloid-Driven T-Cell Exhaustion
Advanced Ovarian Cancer: IV vs IP Chemotherapy With or Without Bevacizumab
Trends in Upfront Surgical Treatment in Advanced Ovarian Cancer: Where Does Neoadjuvant Chemotherapy Fit?
Does Risk-Reducing Salpingo-Oophorectomy Increase Long-Term Cardiovascular Risk?
Can Intraperitoneal Ropivacaine Accelerate Recovery From Advanced Ovarian Cancer Surgery?
Targeting Immune Cell Molecules May Improve Chemotherapy Response in HGSOC
Evaluating the Clinical Utility of FRα as a Therapeutic Target in Ovarian Cancer
Germline Genetic Testing for Breast and Ovarian Cancer Risk in the United Arab Emirates
Long-Term Effects of PARP Inhibitors in HRD-Positive Ovarian Cancer
Researchers Share Unexpected Finding in Development of New Model for Ovarian Cancer
Chemotherapy Before or After Surgery in Advanced Ovarian Cancer: Comparing Outcomes
Individualized Niraparib Dosing for Platinum-Sensitive Recurrent Ovarian Cancer
Does IgA Affect Antitumor Activity of Immune Cells in Ovarian Cancer?
WEE1 Inhibitor Adavosertib Plus Gemcitabine in High-Grade Serous Ovarian Cancer
Gemogenovatucel-T Immunotherapy for Ovarian Cancer Maintenance
Prospective Pilot Study: Streamlining Genetic Testing for Newly Diagnosed Ovarian Cancer
Does Assisted Reproductive Technology Increase the Risk for Ovarian Carcinoma?
Identifying Gene Mutations in Patients With High-Grade Serious Ovarian Carcinoma
Role of Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer
Case Study: Olaparib Maintenance for High-Grade Serous Ovarian Cancer With Brain Metastases
Chemotherapy-Induced Changes to the Tumor Microenvironment and Outcomes in Ovarian Cancer
Oncologist-Initiated Genetic Testing Versus Genetics Referral for Ovarian Cancer Subtype
Combination ATR and PARP Inhibition Under Study in Relapsed Ovarian Cancer
Primary Treatment and Survival in Advanced-Stage Epithelial Ovarian Cancer: U.S. Trends
Are There Racial Differences in Germ Cell and Sex Cord Stromal Ovarian Tumors?
Surveillance Patterns After Treatment for Primary Epithelial Ovarian Cancer
Nutritional Status of Patients With Ovarian Cancer: Carotenoids and Fat-Soluble Vitamins
Advanced Ovarian Cancer: Does Adding HIPEC to Cytoreductive Surgery Improve Outcomes?
First‐Line Treatment of Ovarian Cancer: Weekly Carboplatin/Paclitaxel Versus Standard Regimen
Bevacizumab-Induced Arthralgia in Patients With Advanced Ovarian Cancer
Intrathoracic Disease and Advanced Ovarian Cancer: Focus on Video-Assisted Surgery
Rucaparib Maintenance for Recurrent Ovarian Carcinoma: Update From ARIEL3
Integrin Inhibitor Under Study as Targeted Therapy for Ovarian Cancer
Maintenance Olaparib for Ovarian Cancer: Subgroup Analysis From SOLO1 Trial
Social Media Survey: How COVID-19 Is Affecting Gynecologic Oncology Practice
Differences in Race/Ethnicity and Survival Outcomes in Epithelial Ovarian Cancer
Saving Fertility: Success After Surgery for Borderline Ovarian Tumors?
Comparison of Chemotherapy Regimens for Newly Diagnosed Ovarian Cancer
Are Papanicolaou Tests Useful in Diagnosing Ovarian Cancer?
Use of Apatinib in Platinum-Resistant Epithelial Ovarian Cancer
Secondary Cytoreductive Surgery Plus Niraparib for Recurrent Ovarian Cancer Under Study
Novel Antibody-Drug Conjugate Under Study in Platinum-Sensitive Ovarian Cancer
Combination Therapy of Vaccine and Durvalumab in Advanced Ovarian Cancer
SGO Clinical Practice Statement on Hormone Therapy for Certain Gynecologic Cancers
Phase II EVOLVE Trial: Genomic Mechanisms of Resistance to PARP Inhibitors
Consequences of Frequent Imaging in Recurrent Advanced Ovarian Cancer
Olaparib Treatment for Platinum-Sensitive Relapsed Ovarian Cancer: SOLO3 Trial
ARIEL3 Trial Update on Rucaparib Maintenance for Recurrent Ovarian Cancer
Feasibility of Reducing One Cycle of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
COVID-19 and Ovarian Cancer: Shared Experiences From Japan and Korea
Study Finds Disney Films Offer Surprising Benefits for Women Treated for Gynecologic Cancer
Head-to-Head Trial Compares Bevacizumab/Platinum-Based Regimens in Recurrent Ovarian Cancer
Is Endosalpingiosis Associated With Higher Rates of Ovarian Cancer?
Complications After Primary Cytoreduction for Advanced Ovarian Cancer
Identifying Molecular Mechanisms Driving Ovarian Cancer
Biomarkers May Predict Sensitivity to Combined PARP and PD-1 Inhibition in Ovarian Cancer
Gemcitabine Plus Bevacizumab for Platinum-Resistant Gynecologic Cancers
Can Breastfeeding Reduce the Risk for Ovarian Cancer?
Diagnostic Panel for Ovarian Mucinous Neoplasms
Characterization of Exosomes From Ovarian Cancer and Ovarian Epithelial Cells
Genetic Change May Distinguish Rare Benign Ovarian Tumors From Cancerous Tumors
Cyclophilin A: Potential Therapeutic Target in Serous Ovarian Cancer?
Can Cervical Scrapings From Pap Tests Detect Ovarian Cancer?
Maintenance Olaparib in Advanced Ovarian Cancer: PAOLA-1 Trial
Two Prediction Models Evaluate CA125 and Ovarian Cancer Risk
Everolimus Plus Bevacizumab in Recurrent Ovarian Cancer
Heat Shock Protein 90: Key Player in New Ovarian Cancer Research
Weekly Dose-Dense Paclitaxel in Ovarian Cancer: ICON8 Trial
Niraparib in Newly Diagnosed Advanced Ovarian Cancer
How Does Secondary Surgical Cytoreduction Compare With Chemotherapy for Recurrent Ovarian Cancer?
Olaparib Plus Durvalumab Treatment of BRCA-Mutant Ovarian Cancer: MEDIOLA Trial
Can Metformin Play a Role in Preventing Ovarian Cancer?
Adding Vistusertib to Paclitaxel in Platinum-Resistant Ovarian Cancer
New Imaging Method May Improve Accuracy of Classifying Peritoneal Metastases
Ovarian Cancer Exosomes Promote Niche Formation for Metastatic Growth
VELIA/GOG-3005 Trial Update on PARP Inhibitor in Ovarian Cancer
Do Intrauterine Devices Offer Benefits Beyond Contraception?
Researchers Identify Molecular Origin of Mucinous Ovarian Carcinoma
Niraparib Maintenance Versus Surveillance in Recurrent Ovarian Cancer
Posttraumatic Stress Disorder Linked to Higher Risk of Ovarian Cancer, Study Finds
Pamiparib Plus Tislelizumab Being Studied Further in Ovarian Cancer
Linking Ovarian Cancer and Cervicovaginal Microbiota
Niraparib Plus Pembrolizumab in Recurrent Platinum-Resistant Ovarian Carcinoma
Bevacizumab for Ovarian Cancer: Final Overall Survival Analysis of GOG-0218
Role of BRCA Mutation in Hypersensitivity Reactions to Chemotherapy in Ovarian Cancer
Is Adding Entinostat to Avelumab of Benefit in Treating Advanced Epithelial Ovarian Cancer?
Link Between Folate Deficiency and Olaparib Treatment in Ovarian Cancer: Case Reports
ENGOT-OV16/NOVA Trial: Niraparib Maintenance for Recurrent Ovarian Cancer
Long Noncoding RNAs in a Risk Score System for Ovarian Cancer
Ribociclib and Letrozole Combination Therapy for Ovarian and Endometrial Cancers
Targeting Ovarian Cancer With Combination of PARP Inhibitors and Senolytic Agents
Intensity-Modulated Radiotherapy and Preservation of Ovarian Function
Role of Activated Endothelial Cells in Recurrent Ovarian Cancer
Phase III Trial Results of Trebananib Combination Therapy in Ovarian Cancer
Genetic Testing for Patients With Ovarian Cancers: Can Counseling Improve Decision-Making?
Might Circulating Tumor DNA Guide Clinical Decisions in Aggressive Ovarian Cancer?
IV Versus IP Chemotherapy Plus Bevacizumab in Advanced Ovarian Cancer
Long-Term Fatigue Among Survivors of Epithelial Ovarian Cancer
QUADRA Trial: Niraparib Active in Late-Line Ovarian Cancer
Novel Microscopic Imaging System for Ovarian Tumor Surgery
AACR Special Conference: Questions to Be Answered in Ovarian Cancer Research and Treatment
Genetic Testing in Ovarian and Breast Cancer
Improving Detection of Ovarian Cancer With the CA125 Biomarker
Is Female Infertility Associated With a Higher Risk of Cancer?
Treatment With Avelumab in Resistant Ovarian Cancer
Cediranib Plus Olaparib in Relapsed Platinum-Sensitive Ovarian Cancer
Ovarian Carcinosarcoma: Update on a Rare Malignancy
Risk of Ovarian Cancer After Radical Cystectomy for Bladder Cancer
Conservative Management Approach to Benign Ovarian Cysts and Risk of Complications
Tisotumab Vedotin Exhibits Antitumor Activity in Ovarian Cancer, Among Other Cancers
Atypical Histologic Type of Ovarian Cancer and Cowden Syndrome
Costs of Surgical Care for Women With Ovarian Cancer
Using Artificial Intelligence Tool to Identify Aggressive Ovarian Cancer Cells
Maintenance Olaparib in Newly Diagnosed Advanced Ovarian Cancer
International Surveys Focus on Surgical Practice Patterns in Advanced Ovarian Cancer
PALB2 Mutation in Hereditary Breast and Ovarian Cancer
Association Between Risk of Ovarian Cancer and Ultrasonography Findings
Comparing Neoadjuvant Chemotherapy and Debulking Surgery in Advanced Tubo-Ovarian Cancers
Chemosensitivity Mediator and Immunotherapy Target Identified in Ovarian Cancer
Preclinical Study Finds HDAC Inhibitor’s Effect Tied to Immunity Status
Impact of Low-Dose Aspirin Use on Risk of Ovarian Cancer
Can Patient-Derived Ovarian Cancer Organoids Aid in Treatment Selection?
Investigating Resistance to EZH2 Inhibition in ARID1A-Mutated Ovarian Cancer Cells
Population-Level Genomic Screening for Hereditary Ovarian Cancer
Epidural Anesthesia During Primary Debulking Surgery for Advanced Ovarian Cancer
Can Ketogenic Diet Benefit Women With Gynecologic Cancer?
Do Oral Contraceptives Reduce the Risk of Ovarian Cancer?
Consensus Classifier Algorithm Developed to Aid in Tumor Subtype Identification
Alternative to Paclitaxel Under Study in Ovarian and Uterine Cancers
Niraparib Maintenance for Recurrent Ovarian Cancer: Quality-of-Life Results
Does Adding Sorafenib to Topotecan Improve Survival in Platinum-Resistant Ovarian Cancer?
Impact of Olaparib Maintenance Therapy on Outcomes in Ovarian Cancer
Early Serous Proliferations in Fallopian Tube and Advanced High-Grade Ovarian Cancer
Can Use of Analgesics Improve Survival in Women With Ovarian Cancer?
Tumor Treating Fields Combined With Paclitaxel: Safety Results From Pilot Study
Association Between Analgesic Use and Risk of Ovarian Cancer
Parameters for Dose Reduction in Niraparib Therapy for Ovarian Cancer
Novel Antibody-Drug Conjugate in Platinum-Resistant Ovarian Cancer
Does Hormone Replacement Therapy After Oophorectomy Affect Breast Cancer Risk in BRCA1-Mutation Carriers?
Disparities in Genetic Testing for Hereditary Ovarian Cancer in the United States
Patient-Centered Website Focuses on Psychosocial Issues in Patients With Ovarian Cancer
ESMO Clinical Practice Guidelines for Nonepithelial Ovarian Cancer
Does Modified IP Chemotherapy Regimen Improve Tolerability in Patients With Ovarian Cancer?
Novel Counseling Model for Genetic Testing in Patients With Ovarian Cancer
Tumor Grade and Rate of Lymph Node Metastasis in Early-Stage Ovarian Cancer
Secondary Cytoreductive Surgery for Platinum-Sensitive Epithelial Ovarian Cancer
Genetic Biomarker as Potential Predictor of Platinum Sensitivity in Serous Ovarian Tumors
Pilot Clinical Trial of Dendritic Cell Vaccination in Ovarian Cancer
Molecular Subsets of High-Grade Serous Ovarian Tumors May Impact Future Treatments
Do Some Women Inherit Ovarian Cancer From Their Fathers?
Identifying New Clinical Trial Endpoints in the Treatment of Ovarian Cancer
Familial Link Between Testicular Cancer in Men and Ovarian Cancer in Female Relatives
Population-Based Analysis of Fallopian Tube Carcinoma Rates
Prognostic Significance of Genomic Rearrangement Patterns in High-Grade Serous Ovarian Cancer
Impact of Intraperitoneal Chemotherapy on Survival in Advanced Ovarian Cancer
Paclitaxel Plus Pazopanib in Recurrent Ovarian Cancer
Rucaparib Maintenance Therapy for Platinum-Sensitive Ovarian Cancer
Does Small Cell Ovarian Cancer Respond to Immunotherapy?
Managing Toxicities With Niraparib in Maintenance Therapy for Ovarian Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.